Aletheia · Disclosure Card
Divi's Laboratories
DIVISLAB · Pharma
MARKET CAP
₹1.2L Cr
PE
68.4x
PB
8.4x
ROE
12.8%
REV GROWTH
18.4%
DISCLOSURE HEALTH SCORE
Passes most checks. Verify the noted areas before increasing position.
ROCE of 14.8% is marginal. Business may be destroying economic value depending on cost of capital.
OCF/PAT ratio of 0.96 — broadly in line with profit. Minor non-cash items at play.
No promoter pledge. Promoter holding is unencumbered — full alignment with minority shareholders.
Zero debt. Complete financial flexibility and no forced deleveraging risk.
FCF yield of 1.4%. Low but positive. Growth capex may be absorbing cash — verify capex is productive.
Data is representative and for educational purposes only. Not investment advice. Verify all data on Screener.in, BSE, or NSE before any investment decision.